(2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid

We are (2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid CAS:80082-65-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid
CAS.NO:80082-65-1
Synonyms:AMA
(2S-trans)-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid
Molecular Formula:C4H8N2O4S
Molecular Weight:180.18200
 
Physical and Chemical Properties:
Density:1.75
Boiling point:206-211ºC
Index of Refraction:1.627
 
Specification:
Appearance:Off-white to white powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For the synthesis of aztreonam

(2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid


Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire. Clorhidrato de 1- [2-amino-1- (4-metoxifenil) etil] ciclohexanol CAS:130198-05-9 At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.Clorhidrato de 2H, 4H, 5H, 6H, 7H, 7AH-Thieno [3,2-c] piridin-2-ona CAS:115473-15-9 At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.Dichloromethylphenylsilane CAS:149-74-6 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.

Related Products
Product Name
4-Pentylbenzeneboronic acid View Details
N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline View Details
5-Methylpyridine-2,3-dicarboxylic acid View Details
1,3,5-Tri-O-Benzoyl-2-Deoxy-2-Fluoro -α-D-Arabinose manufacturer Octocrilene manufacturer Methyl Methoxyacetate manufacturer 6-Bromo-5-chloropyridin-3-amine manufacturer 2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole manufacturer